Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the Middle East

Joint Authors

Sulaiman, Kazim
al-Mutarib, Ahmad
Rajan, Rajesh
Dashti, Raja
Bulbanat, Bassam
al-Suwayyid, Jasim
Bazargani, Nooshin
Panduranga, Prashanth
al-Jar Allah, Muhammad
al-Zakwani, Ibrahim
Ridha, Mustafa
Amin, Haitham
Asaad, Nidal
al-Falih, Husam
al-Mahmid, Wail
al-Asfar, Abd al-Fatah A.
al-Habib, Khalid F.

Source

Oman Medical Journal

Issue

Vol. 35, Issue 1 (31 Jan. 2020)8 p.

Publisher

Oman Medical Specialty Board

Publication Date

2020-01-31

Country of Publication

Oman

No. of Pages

8

Main Topic

Diseases

Abstract EN

We sought to estimate the mortality and morbidity in diabetic acute heart failure (AHF) patients stratified by left ventricular ejection fraction.

Methods: We analyzed the data of patients with AHF from seven Middle Eastern countries (Bahrain, Oman, Yemen, Kuwait, UAE, Qatar, and Saudi Arabia) from February to November 2012, who were enrolled in a multinational registry of patients with heart failure (HF).

Results: A total of 2258 AHF patients had diabetes mellitus.

The mean age was 63.0±11.0 years (ranging from 18 to 99 years), and 60.3% (n = 1362) of the patients were males.

The mean ejection fraction (EF) was 37.0±13.0%.

HF with reduced EF (< 40%) (HFrEF) was observed in 1268 patients (56.2%), whereas 515 patients (22.8%) had mid-range (40–49%) (HFmrEF) and 475 patients (21.0%) had preserved EF (≥ 50%) (HFpEF).

The overall cumulative all-cause mortalities at three- and 12-months follow-up were 11.8% (n = 266) and 20.7% (n = 467), respectively.

Those with HFpEF were associated with lower three-months cumulative all-cause mortality compared to those with HFrEF (7.6% vs.

5.9%; adjusted odds ratio (aOR) = 0.54, 95% confidence interval (CI): 0.31–0.95; p = 0.031), but not significantly different when compared to those with HFmrEF (aOR = 0.86, 95% CI: 0.53–1.40; p = 0.554).

There were largely no significant differences among the groups with regards to the 12-months all-cause cumulative mortality (11% vs.

11% vs.

10%; p = 0.984).

There were also no significant differences in re-hospitalization rates between the three HF groups not only at three months (23% vs.

20% vs.

22%; p = 0.520), but at one-year follow-up (28% vs.

30% vs.

32%; p = 0.335).

Conclusions: Three-month cumulative all-cause mortality was high in diabetic HFrEF patients when compared to those with HFpEF.

However, there were no significant differences in mortality at one-year follow-up between the HF groups.

There were also no significant differences in re-hospitalization rates between the HF groups not only at three months but also at one-year follow-up in the Middle East.

American Psychological Association (APA)

al-Jar Allah, Muhammad& Rajan, Rajesh& al-Zakwani, Ibrahim& Dashti, Raja& Bulbanat, Bassam& al-Shaykh Ali, Alawi A.…[et al.]. 2020. Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the Middle East. Oman Medical Journal،Vol. 35, no. 1.
https://search.emarefa.net/detail/BIM-955467

Modern Language Association (MLA)

al-Shaykh Ali, Alawi A.…[et al.]. Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the Middle East. Oman Medical Journal Vol. 35, no. 1 (Jan. 2020).
https://search.emarefa.net/detail/BIM-955467

American Medical Association (AMA)

al-Jar Allah, Muhammad& Rajan, Rajesh& al-Zakwani, Ibrahim& Dashti, Raja& Bulbanat, Bassam& al-Shaykh Ali, Alawi A.…[et al.]. Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the Middle East. Oman Medical Journal. 2020. Vol. 35, no. 1.
https://search.emarefa.net/detail/BIM-955467

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-955467